Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

NCT00993720 on ClinicalTrials.gov · last registry update 2011-01-21

A small phase 2/phase 3 — 30 participants, against a typical 60. The sponsor logged completion for October 2010. Primary outcome, as filed: insulin-dose. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2/P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hvidovre University Hospital
Sponsor type: Other
Enrollment: 30
Started: 2009-10
Primary completion: 2010-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

insulin-dose

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.